Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lumicitabine
- Development stage
- Discontinued
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lumicitabine (ALS-8176) is an orally bioavailable nucleoside analog prodrug designed for the treatment of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. Developed by Alios BioPharma and later acquired by Janssen, the drug is metabolized into its active triphosphate form, which acts as a potent inhibitor of the viral RNA-dependent RNA polymerase (RdRp). By mimicking natural nucleosides, it incorporates into the nascent viral RNA chain, leading to premature chain termination and a significant reduction in viral load. Clinical development reached Phase 2 for both RSV in infants and adults, as well as hMPV, but Janssen discontinued the program in late 2020 following a strategic portfolio review.
- Other names
- 2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-diisobutyrate
02
Targets
RSV L (Respiratory syncytial virus L protein)
Beyond the preview
Go deeper on lumicitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lumicitabine.